At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,109 enrolled
Drug / intervention
levofloxacindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Sep 21, 2005·Updated Jun 10, 2011
In Brief
A Phase 3 clinical trial evaluating levofloxacin for Urinary Tract Infections and Pyelonephritis. Completed, enrolled 1,109 participants.
Detailed Summary
The purpose of this study is to evaluate the effectiveness and safety of two antibiotics in the treatment of complicated urinary tract infection or acute pyelonephritis (kidney infection). A 5-day course of 750 milligrams of levofloxacin given intravenously and/or by mouth once daily will be compared to a 10-day course of 400 milligrams of ciprofloxacin given intravenously and/or 500 milligrams of ciprofloxacin given by mouth twice daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infections, Pyelonephritis
Countries--
CollaboratorsPriCara, Unit of Ortho-McNeil, Inc.
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedSep 2005
Study CompletionApr 2006
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartOct 1, 2004
Study CompletionApr 1, 2006
TodayJul 2, 2026
Posted 20.8 years ago
Interventions
levofloxacindrug